Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ceramide in preparation of kit for evaluating adverse event risks of heart failure patients

A technology of ceramide and heart failure, applied in the field of application of ceramide in the preparation of a kit for evaluating the risk of adverse events in patients with heart failure

Pending Publication Date: 2020-10-27
BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES
View PDF5 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are no good biomarkers to predict its poor prognosis, and the changes in energy metabolism during the development of heart failure may indicate different stages of disease development, so more markers are still needed to predict the prognosis of heart failure There is no effective way to reduce the morbidity and mortality of patients with heart failure when the pathological mechanism is still uncertain, and there is an urgent need for new markers to assist the diagnosis, treatment and clinical management of heart failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ceramide in preparation of kit for evaluating adverse event risks of heart failure patients
  • Application of ceramide in preparation of kit for evaluating adverse event risks of heart failure patients
  • Application of ceramide in preparation of kit for evaluating adverse event risks of heart failure patients

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] After 255 patients with heart failure (HF patients) were followed up for an average of 568 days, 45 died and 4 underwent heart transplantation. Outcome events were all-cause death and heart transplantation. Higher Cer(d18:1 / 16:0 / d18:1 / 24:0) ratio levels in heart failure patients were significantly associated with all-cause mortality and cardiac transplantation events (log rank<0.005).

[0062] like figure 1 As shown, the levels of different types of ceramides were compared between age-sex-matched healthy people (n=40) and HF patients (n=40). Among them, Cer(d18:1 / 16:0), Cer(d18:1 / 18:0), Cer(d18:1 / 20:0), and Cer(d18:1 / 24:1) had significant differences.

[0063] like figure 2 Shown is the scatter diagram of the differences in various ceramide levels in patients with end-stage heart failure, in which Cer(d18:1 / 16:0) was higher in the group with adverse events (P<0.005), and Cer(d18:1 / 16:0) was higher in the group with adverse events (P<0.005), 24:0) were lower (P<0.05...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a product for detecting ceramide in preparation of a kit. The application of the kit is at least one of the following (a1)-(a3): (a1) screening or assisting in diagnosing heart failure patients; (a2) evaluating or assisting in evaluating the prognosis risk of heart failure patients; and (a3) evaluating or assisting in evaluating the adverse event risk of heart failure patients. Research results show that the ratio of plasma ceramide cer (d18: 1 / 16: 0) to cer (d18: 1 / 24: 0) is an important predictive factor for the occurrence of adverse events of heart failure in patients with heart failure at the final stage, and is independent of currently used lipid markers, which facilitates the identification of high risk patients requiring more positive therapeutic interventions.

Description

technical field [0001] The invention relates to the application of ceramide in the preparation of a kit for evaluating the risk of adverse events in patients with heart failure. Background technique [0002] As the terminal stage of various cardiovascular diseases, heart failure is a progressive disease with high morbidity and high hospitalization rate. At present, there are no good biomarkers to predict its poor prognosis, and the changes in energy metabolism during the development of heart failure may indicate different stages of disease development, so more markers are still needed to predict the prognosis of heart failure There is no effective way to reduce the morbidity and mortality of patients with heart failure when the pathological mechanism is still uncertain, and there is an urgent need for new markers to assist the diagnosis, treatment and clinical management of heart failure. Contents of the invention [0003] The purpose of the present invention is to provid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02
CPCG01N30/02
Inventor 杜杰王媛任璐檀鑫李凤娟王雪蒋洪峰
Owner BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com